Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
September 29, 2021 08:05 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit
August 23, 2021 07:30 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update
August 16, 2021 16:01 ET
|
Athira Pharma, Inc.
- Initiated open label extension for LIFT-AD and ACT-AD trials of ATH-1017 allowing for an additional six months of treatment - ACT-AD and LIFT-AD are actively recruiting; topline data of...
Athira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada, M.D.
August 05, 2021 16:56 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
July 19, 2021 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
July 06, 2021 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., July 06, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company
June 17, 2021 17:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., June 17, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira“), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore...
Athira Pharma Appoints Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy
June 14, 2021 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma to Present at Upcoming Investor Conferences
June 09, 2021 07:00 ET
|
Athira Pharma, Inc.
– JMP Securities Life Sciences Conference – Raymond James Human Health Innovation Conference BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA)...
Athira Pharma Appoints Mark Worthington as General Counsel
June 01, 2021 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., June 01, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...